SecBot SecBot
PRESS-RELEASE ·Filed Mar 18, 2026

MDAI

Spectral AI, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

This funding de-risks the path to FDA authorization and commercialization of the DeepView System. Traders should monitor for upcoming FDA decision timelines and potential near-term catalysts. The non-dilutive nature of the funding is a positive signal for shareholders, avoiding near-term equity dilution.

DirectionBullish
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
MDAI ▲ +29.58% at T+60d
LONG call ✓ call won +29.58% · α vs SPY +15.23% · entry $1.42 → $1.84
Entry = T+0 close
Mar 18, 2026
via day close
T+1d
+8.45%
call +8.45% · α +10.19%
$1.54
settled 7mo ago
T+5d
+7.04%
call +7.04% · α +9.25%
$1.52
settled 7mo ago
T+20d
+33.10%
call +33.10% · α +25.48%
$1.89
settled 6mo ago
T+60d
+29.58%
call +29.58% · α +15.23%
$1.84
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Spectral AI (MDAI) announced $31.7 million in additional non-dilutive funding from BARDA to advance development of its DeepView® System, an AI-powered burn wound imaging technology. The funding accelerates Phase II development, including total body surface area mapping, and supports FDA clearance efforts. The company is also contributing $9.7 million to the project, which is part of a larger contract valued up to $150 million.

Key Financial Metrics

Deal Value
$31.7M

Key Facts

  • Spectral AI received $31.7 million in new non-dilutive funding from BARDA.
  • Company committed to contribute an additional $9.7 million to development costs.
  • Total BARDA contract value remains up to $150 million, with $54.9 million previously committed and now $31.7 million newly advanced.
  • Funding supports FDA clearance and development of DeepView System, including total body surface area mapping.
  • DeepView System targets use in emergency departments, trauma centers, and as a medical countermeasure for mass burn incidents.

Financial Impact

$31.7 million in non-dilutive capital received, reducing near-term financing risk; $9.7 million in additional company investment

cashR&D spenddilution

Risk Factors

  • FDA clearance is not guaranteed and remains a key regulatory hurdle.
  • Commercial adoption may be slow despite government support.
  • Company must still contribute $9.7 million, which could pressure cash reserves if not offset by future funding.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258593
5 reports for MDAI
Performance horizon
Filters
Rows
Reports for MDAI — sortable, filterable
TypeNow
Aug 12, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$1.73awaiting T+60—$1.50 (−13.29%)
Jul 8, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$1.72 $1.66▼ −3.49%▼ −5.12%$1.50 (−12.79%)
Mar 24, 2026
30w ago
Press Release
MIXED ★ 6/10
$1.54 $1.76▲ +14.15%▲ +0.69%$1.50 (−2.60%)
Mar 18, 2026
31w ago
Press Release
BULLISH ★ 8/10
$1.42 $1.84▲ +29.58%▲ +15.23%$1.50 (+5.63%)
Mar 10, 2026
32w ago
Press Release
NEUTRAL ★ 3/10
$1.40 $1.94▲ +38.57%▲ +26.89%$1.50 (+7.14%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 7h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 18, 2026